Alpha 2.0
Login Register
» Authors » Ayako Ishimori

Ayako Ishimori

Explore the profile of Ayako Ishimori including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 11
Citations 71
Followers 0
Related Specialties
Allergy & Immunology
Pulmonary Medicine
Molecular Biology
Top 10 Co-Authors
Norihiro Harada
Kazuhisa Takahashi
Sonoko Harada
Jun Ito
Ryo Atsuta
Kei Matsuno
Yoko Katsura
Hisaya Akiba
Fumihiko Makino
Tomohito Takeshige
Published In
Allergol Int
Exp Lung Res
J Asthma
Sci Rep
Curr Issues Mol Biol
Affiliations
Soon will be listed here.
Recent Articles
1.
MAP3K19 Affects TWEAK-Induced Response in Cultured Bronchial Epithelial Cells and Regulates Allergic Airway Inflammation in an Asthma Murine Model
Sandhu Y, Harada N, Harada S, Nishimaki T, Sasano H, Tanabe Y, et al.
Curr Issues Mol Biol . 2023 Nov; 45(11):8907-8924. PMID: 37998736
The mitogen-activated protein kinase (MAPK) signaling pathway is involved in the epithelial-mesenchymal transition (EMT) and asthma; however, the role of mitogen-activated protein kinase kinase kinase 19 (MAP3K19) remains uncertain. Therefore,...
2.
Pretreatment circulating MAIT cells, neutrophils, and periostin predicted the real-world response after 1-year mepolizumab treatment in asthmatics
Sasano H, Harada N, Harada S, Takeshige T, Sandhu Y, Tanabe Y, et al.
Allergol Int . 2023 Jun; 73(1):94-106. PMID: 37336695
Background: Mepolizumab treatment improves symptom control and quality of life and reduces exacerbations in patients with severe eosinophilic asthma. However, biomarkers that predict therapeutic effectiveness must be determined for use...
3.
Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma
Sandhu Y, Harada N, Sasano H, Harada S, Ueda S, Takeshige T, et al.
Biomolecules . 2023 Mar; 13(3). PMID: 36979473
Benralizumab treatment reduces exacerbations and improves symptom control and quality of life in patients with severe eosinophilic asthma. However, the determination of biomarkers that predict therapeutic effectiveness is required for...
4.
Chitin induces steroid-resistant airway inflammation and airway hyperresponsiveness in mice
Takeshige T, Harada N, Harada S, Ishimori A, Katsura Y, Sasano H, et al.
Allergol Int . 2021 Feb; 70(3):343-350. PMID: 33640239
Background: Previous reports have shown that pathogen-associated patterns (PAMPs) induce the production of interleukin (IL)-1β in macrophages. Moreover, studies using mouse models also suggest that chitin, which acts as a...
5.
Combination of TWEAK and TGF-β1 induces the production of TSLP, RANTES, and TARC in BEAS-2B human bronchial epithelial cells during epithelial-mesenchymal transition
Matsuno K, Harada N, Harada S, Takeshige T, Ishimori A, Itoigawa Y, et al.
Exp Lung Res . 2019 Jan; 44(7):332-343. PMID: 30676129
Aim Of The Study: In patients with asthma, chronic inflammatory processes and the subsequent remodeling of the airways contribute to the symptoms and the pathophysiological changes. Epithelial-mesenchymal transition (EMT) is...
6.
Characterization of tenascin-C as a novel biomarker for asthma: utility of tenascin-C in combination with periostin or immunoglobulin E
Yasuda M, Harada N, Harada S, Ishimori A, Katsura Y, Itoigawa Y, et al.
Allergy Asthma Clin Immunol . 2018 Nov; 14:72. PMID: 30473714
Background: Extracellular matrix proteins tenascin-C (TNC) and periostin, which were identified as T-helper cell type 2 cytokine-induced genes in human bronchial epithelial cells, accumulate in the airway basement membrane of...
7.
Difference between two exhaled nitric oxide analyzers, NIOX VERO electrochemical hand-held analyzer and NOA280i chemiluminescence stationary analyzer
Tanabe Y, Harada N, Ito J, Matsuno K, Takeshige T, Harada S, et al.
J Asthma . 2018 Oct; 56(2):167-172. PMID: 30335533
Background: Fractional exhaled nitric oxide (FE) is useful for the evaluation of eosinophilic airway inflammation, including that seen in asthma. Although a new electrochemical hand-held FE analyzer, the NIOX VERO...
8.
Leukotriene B receptor type 2 protects against pneumolysin-dependent acute lung injury
Shigematsu M, Koga T, Ishimori A, Saeki K, Ishii Y, Taketomi Y, et al.
Sci Rep . 2016 Oct; 6:34560. PMID: 27703200
Although pneumococcal infection is a serious problem worldwide and has a high mortality rate, the molecular mechanisms underlying the lethality caused by pneumococcus remain elusive. Here, we show that BLT2,...
9.
Circulating activated innate lymphoid cells and mucosal-associated invariant T cells are associated with airflow limitation in patients with asthma
Ishimori A, Harada N, Chiba A, Harada S, Matsuno K, Makino F, et al.
Allergol Int . 2016 Aug; 66(2):302-309. PMID: 27575652
Background: A variety of innate subsets of lymphoid cells such as natural killer (NK) cells, several populations of innate lymphoid cells (ILCs), and mucosal-associated invariant T (MAIT) cells as innate-like...
10.
Evaluation of switching low-dose inhaled corticosteroid to pranlukast for step-down therapy in well-controlled patients with mild persistent asthma
Harada S, Harada N, Itoigawa Y, Katsura Y, Kasuga F, Ishimori A, et al.
J Asthma . 2015 Sep; 53(2):207-12. PMID: 26325232
Objective: Treatment guidelines for asthma recommend step-down therapy for well-controlled asthma patients. However, the precise strategy for step-down therapy has not been well defined. We investigated whether well-controlled patients with...